Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Open accessAbstract
Retinal gene therapy has come a long way in the last few decades and the development and improvement of new gene delivery technologies has been exponential. The recent promising results from the first clinical trials for inherited retinal degeneration due to mutations in RPE65 have provided a major breakthrough in the field and have helped cement the use of recombinant adeno-associated viruses (AAV) as the major tool for retinal gene supplementation. One of the key problems of AAV however, is its limited capacity for packaging genomic information to a maximum of around 4.8 kb. Previous studies have demonstrated that homologous recombination and/or inverted terminal repeat (ITR) mediated concatemerization of two overlapping AAV vectors can partially overcome the size limitation and help deliver larger transgenes. The aim of this study was to investigate and compare the use of different AAV dual-vector approaches in the mouse retina using a systematic approach comparing efficiencies in vitro and in vivo using a unique oversized reporter construct. We show that the hybrid approach relying on vector genome concatemerization by highly recombinogenic sequences and ITRs sequence overlap offers the best levels of reconstitution both in vitro and in vivo compared to trans-splicing and overlap strategies. Our data also demonstrate that dose and vector serotype do not affect reconstitution efficiency but a discrepancy between mRNA and protein expression data suggests a bottleneck affecting translation.
AI snapshot
Written from the paper’s full text.
TL;DR
This study systematically compared dual AAV vector strategies (trans-splicing, overlapping, hybrid) for delivering an oversized lacZ reporter to HEK293 cells and mouse retina. The hybrid strategy gave the highest in vivo reconstitution (~9% of control), but reconstitution was low overall and mRNA levels (~60%) far exceeded protein levels (~10%), suggesting a translation bottleneck.
Key findings
- In vitro, dual-vector β-galactosidase reconstitution efficiencies were 10.3% (trans-splicing, TS), 15.3% (hybrid, HB), and 17.4% (overlap, OL) of CMV.lacZ control; OL was numerically highest in this assay.
- In vivo in mouse retina, HB reconstitution was 9.07% of control, TS was 1.78%, and OL was below assay background (−0.67% ± SEM 0.54); HB was therefore the most efficient in vivo.
- Serotype did not change HB reconstitution: AAV8 gave 9.07% and Anc80L65 gave 9.57%, despite the Anc80L65 CMV.lacZ control being 14-fold higher than AAV8.
- Dose effects: in vitro HB efficiency rose from 8.4% to 15.1% to 17.7% at MOI 1E7, 1E8, and 1E9; in vivo a 5-fold dose increase produced only 2.2-fold mRNA and 1.5-fold protein increases, and mRNA suggested ~60% reconstitution versus ~10% by protein.
Methods
- An oversized Rainbow reporter (mCherry, lacZ, Gluc, and eGFP separated by furin-2A cleavage sites) was split within lacZ into left and right vectors; dual strategies were OL, TS, and HB, with CMV.lacZ as control.
- In vitro: HEK293 cells were transduced with AAV2/2 dual vectors at defined MOIs, and β-galactosidase was quantified after 48 h. In vivo: C57BL/6J-Tyrc-2J/J male mice (6–8 weeks) received subretinal injections of AAV2/8 or Anc80L65 dual vectors at low dose 3E9 vg/eye or high dose 1.5E10 vg/eye; 4–6 eyes per group; retinas were collected 4 weeks post-injection.
- β-galactosidase activity was normalized to CMV.lacZ controls and corrected for plasmid reconstitution rates; lacZ mRNA was measured by qPCR using the ΔCT method with GAPDH as reference; two-tail Student’s t-test was used with significance at p < 0.01.
Limitations
- Stated: dual AAV reconstitution remains low and the cellular mechanisms are poorly understood; mRNA and protein levels may be inherently flawed indicators of reconstitution without identical-sequence controls; oversized monocistronic controls cannot be used; OL efficiency is gene- and sequence-dependent; in vivo work used subretinal injection only, not intravitreal delivery.
- Stated: HB reconstitution may be sensitive to minor sequence or ITR variations, and the intein-based alternative has not been thoroughly characterized.
- Evident from the text: findings come from one oversized reporter in HEK293 cells and mouse retina, with 4–6 eyes per group and 1–2 in vitro assays in triplicate; no human data are reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
19 of 28 cited sources checked · 10 supported · 1 flagged · accuracy not yet measured
- Premisecitation
Due to lack of proper controls and accurate protein quantification methods, determining parameters for clinical approaches has been lacking.
“Even though vector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
Quote in the paperSubstantial claim3 of 3 sources checked- cites Dyka et al., 2014 source
The Discussion (page unavailable) says that the amount of protein required for therapy remains an important question, supporting the claim that clinical parameters were not yet established. But the Results section on retinal expression (page unavailable) reports using an oversized single fAAV-MYO7A vector for comparison, contrary to the claimed lack of that control. The Methods and Results also describe semiquantitative protein measurements, though they do not establish accurate quantification of retinal protein levels. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites Trapani et al., 2014 source
The Results (pages not specified in our copy) report comparisons with oversized AAV vectors and quantification of ABCA4 and MYO7A expression, contrary to the attributed lack of controls and protein quantification. The paper also reports testing vector doses and ratios and selecting an optimal regimen for subsequent experiments; it does not identify those alleged deficiencies as the reason clinical parameters were lacking. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites Trapani et al., 2015 source
The Materials and Methods (Western blot analysis; page unavailable) describe relative ABCA4 protein quantification using control lanes. The Discussion (page unavailable) reports variable expression and therapeutic effects, but neither passage says that missing oversized-vector controls or inadequate protein quantification prevented clinical parameters from being determined. Searches for those controls and for clinical parameter thresholds did not establish the claimed causal explanation. (LLM, conf=0.72)
Experimental — accuracy not yet measured
- Premisecitation
Vectors carrying larger genomes have lower transduction capacity, most likely due to preferential degradation of vectors encapsidating larger genomes.
“It has also been shown that vectors carrying larger genomes have lower transduction capacity, most likely due to a preferential degradation of vectors encapsidating larger genomes (Grieger and Samulski, 2005).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Grieger and Samulski, 2005 source
- Premisecitation
AAV has a shortcoming of limited genetic payload capacity.
“However, despite its safety and efficacy as a gene therapy vector, AAV has its shortcomings, one being the limited capacity of its genetic payload (Kotterman and Schaffer, 2014).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Kotterman and Schaffer, 2014 source
- Findingown data
The OL construct containing the largest homology sequence generated the best reconstitution efficiency.
“The construct containing the largest homology sequence generated the best reconstitution efficiency therefore was used hereafter (data not shown).”
Quote in the paperSubstantial claim - Findingown data
The hybrid approach offers the best levels of reconstitution both in vitro and in vivo compared to trans-splicing and overlap strategies.
“We show that the hybrid approach relying on vector genome concatemerization by highly recombinogenic sequences and ITRs sequence overlap offers the best levels of reconstitution both in vitro and in vivo compared to trans-splicing and overlap strategies.”
Quote in the paperSubstantial claim
- Findingown data
In vitro, reconstitution efficiencies increased from 8.4% to 15.1% to 17.7% for doses of 1E7, 1E8, and 1E9, respectively.
“When compared to controls of equal dose, reconstitution efficiencies increased from 8.4 to 15.1 to 17.7% for doses of 1E7, 1E8, and 1E9, respectively.”
Quote in the paperSubstantial claim - Findingown data
All possible Rainbow construct combinations are capable of reconstituting with β-galactosidase levels between 70.6 and 83.4% of the monocistronic CMV.lacZ control.
“The results show that all possible Rainbow construct combinations are capable of reconstituting with β-galactosidase levels between 70.6 and 83.4% of the monocistronic CMV.lacZ control (Figure 2A)”
Quote in the paperSubstantial claim - Findingown data
A 5-fold increase in vector dose resulted in only 2.2-fold and 1.5-fold increases in mRNA and protein levels, respectively.
“however a 5-fold increase in vector dose only resulted in 2.2- and 1.5-fold increases in mRNA and protein levels, respectively.”
Quote in the paperSubstantial claim - Findingreasoning
At doses of 1E8 and 1E9, co-transduction efficiency approaches 100%.
“However, at doses of 1E8 and 1E9 co-transduction efficiency approaches 100%”
Quote in the paperSubstantial claim - Findingnone given
OL reconstitution is dependent on overlapping sequence length, with shorter overlap showing lower efficiencies.
“OL reconstitution is dependent on overlapping sequence length, with shorter overlap showing lower efficiencies (data no shown)”
Quote in the paperNot a substantial claim - Findingown data
In vivo, mRNA levels showed significantly higher rates of reconstitution than protein levels.
“Interestingly mRNA levels (Figure 3B) showed significantly higher rates of reconstitution than protein levels (Figure 3C)”
Quote in the paperNot a substantial claim - Findingown data
Even 100% reconstitution efficiency of hybrid DUO vectors could only result in 83.4% protein levels of CMV-lacZ control.
“Therefore, even 100% reconstitution efficiency of e.g., hybrid DUO vectors could only result in 83.4% protein levels of CMV-lacZ control.”
Quote in the paperSubstantial claim - Findingown data
Reconstitution efficiencies in vitro were 10.3, 15.3, and 17.4% of control for TS, HB, and OL, respectively.
“Based on β-galactosidase levels, reconstitution efficiencies were 10.3, 15.3, and 17.4% of control for TS, HB, and OL, respectively (Figure 2B).”
Quote in the paperSubstantial claim - Findingown data
All mice injected with left construct alone did not have LacZ expression as detected by the qPCR assay.
“All mice injected with left construct alone did not have LacZ expression as detected by the qPCR assay: CT values “not determined” or 36.2+ (data not shown).”
Quote in the paperSubstantial claim - Findingown data
No β-galactosidase was detected in cells transduced with left or right vectors by themselves.
“No β-galactosidase was detected in cells transduced with left or right vectors by themselves (data not shown).”
Quote in the paperSubstantial claim - Findingown data
OL reconstitution efficiency (1,100 bp homology construct) in vivo was below assay background level (−0.67% ± SEM 0.54).
“OL reconstitution efficiency (1,100 bp homology construct) was below assay background level and is therefore not shown (−0.67% ± SEM 0.54).”
Quote in the paperSubstantial claim - Findingown data
Absolute β-galactosidase levels from the control CMV.lacZ vector were 14-fold higher for Anc80L65 than for AAV8.
“a comparison of the absolute levels of β-galactosidase from the control CMV.lacZ vector for each serotype shows that Anc80L65 is 14-fold higher than AAV8 (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Increasing dual vector doses 10- and 100-fold (from 1E7 to 1E8 and 1E9) resulted in corresponding 18- and 103-fold increases in β-galactosidase levels, respectively, when compared to 1E7 control.
“Further, increasing dual vector doses 10- and 100-fold (from 1E7 to 1E8 and 1E9) we see corresponding 18- and 103-fold increases in β-galactosidase levels, respectively when compared to 1E7 control (Figure 2D).”
Quote in the paperSubstantial claim - Findingown data
β-galactosidase levels increased with increasing doses of HB dual vectors in HEK293 cells (8.4%, 15.1%, and 17.7% for 1E+7, 1E+8, and 1E+9 vg, respectively).
“The data show moderately increasing levels of β-galactosidase (8.4%, 15.1% and 17.7% for 1E+7, 1E+8 and 1E+9 vg, respectively) when compared to matching control doses (Figure 2C)”
Quote in the paperSubstantial claim - Findingown data
Anc80L65-transduced retinal cells had an almost identical level of HB reconstitution compared to AAV8 (9.57%).
“As shown in Figure 3A, retinal cell transduced with Anc80L65 had an almost identical level of HB reconstitution compared to AAV8 (9.57%)”
Quote in the paperSubstantial claim - Findingown data
β-galactosidase expression from Rainbow plasmids (original intact and hypothetical reconstituted plasmids containing introns) was lower than from CMV-lacZ plasmid.
“Based on our plasmid transfection experiments β-galactosidase expression from Rainbow plasmids (original intact and hypothetical reconstituted plasmids containing introns, as indicated in Figure 1) was lower than from CMV-lacZ plasmid (Figure 2A).”
Quote in the paperSubstantial claim - Interpretationown data
The increase in β-galactosidase with dose indicates increased co-transfection due to higher MOIs.
“indicating increased co-transfection due to higher MOIs.”
Quote in the paperSubstantial claim - Interpretationown data
lacZ expression from a Rainbow-type cassette was high and only moderately decreased compared to an expression cassette that expresses only lacZ, outside of the other reporter genes.
“illustrating that the lacZ expression from a Rainbow-type cassette was high and only moderately decreased compared to an expression cassette that expresses only lacZ, outside of the other reporter genes.”
Quote in the paperSubstantial claim - Interpretationreasoning
Assessing dual AAV vector reconstitution quantitatively based on mRNA or protein levels may be an inherently flawed approach, as proper controls for these experiments are not feasible.
“Assessing dual AAV vector reconstitution quantitatively based on mRNA or protein levels may thus be an inherently flawed approach, as proper controls for these experiments are not feasible.”
Quote in the paperSubstantial claim - Interpretationreasoning
As dual AAVs are studied in the context of oversized transgenes, oversized monocistronic controls cannot be used.
“As dual AAVs are studied in the context of oversized transgenes, oversized monocistronic controls cannot be used.”
Quote in the paperSubstantial claim - Interpretationreasoning
The minor increase in reconstitution efficiency at high doses suggests that reconstitution is not significantly dependent on intracellular rAAV vector genome amounts.
“and the minor increase in reconstitution efficiency suggests that reconstitution is not significantly dependent on intracellular rAAV vector genome amounts.”
Quote in the paperSubstantial claim - Premisecitation
AAV has a limited packaging capacity of around 4.8 kb.
“One of the key problems of AAV however, is its limited capacity for packaging genomic information to a maximum of around 4.8 kb.”
- Also stated in: § Introduction · plain
“However, one of the main limiting factors of this strategy is the restriction of transgene size that can be packaged into AAV, which is ~4.8 kb (Wu et al., 2010).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Wu et al., 2010
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Also stated in: § Introduction · plain
- Study design and conductnone given
The dual vector reporter construct based on quantification of β-galactosidase enzymatic activity offers better precision than quantification based on western blot band intensity comparisons.
“For this purpose, we generated a dual vector reporter construct approach based on quantification of β-galactosidase enzymatic activity, which offers better precision than quantification based on western blot band intensity comparisons.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Efficiencies with clinical relevance can be achieved with dual AAV vectors.
“indicating that efficiencies with clinical relevance can be achieved.”
Quote in the paperSubstantial claim- Rests on an assumption: In vivo efficiencies of dual AAV vectors of ~5–10% compared to single AAV approaches have been reported.
- Rests on an assumption: In some model systems, dual AAV vector reconstitution has resulted in rescue of a disease phenotype.
- Interpretationreasoning
In OL strategies, sequences will be gene-specific dependent with only a few variables like overlap size and sequence optimization amenable to modifications.
“In the OL strategies, sequences will be gene-specific dependent with only a few variables like overlap size and sequence optimization amenable to modifications.”
Quote in the paperNot a substantial claim - Interpretationcitation
Reconstitution efficiencies depend on transgene sequences.
“However, data from us and others also indicates that these efficiencies depend on transgene sequences, and may possibly be increased by using more recombinogenic overlap and/or ITR sequences (Yan et al., 2005).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Yan et al., 2005 source
- Interpretationown data
Once efficient co-transduction is achieved, further increases in reconstitution efficiencies are not strongly dependent on vector genome amounts.
“taken together these data support our conclusion that once efficient co-transduction is achieved, further increases in reconstitution efficiencies are not strongly dependent of vector genome amounts.”
Quote in the paperSubstantial claim - Interpretationreasoning
For both OL and HB approaches, the homology sequence will be critical in determining the levels of reconstitution.
“For both the OL and HB approaches, the homology sequence will be critical in determining the levels of reconstitution.”
Quote in the paperSubstantial claim - Interpretationown data
The increase in reconstitution efficiency with dose likely reflects increased vector co-transduction efficiency.
“The increase in efficiency likely reflects increased vector co-transduction efficiency.”
Quote in the paperSubstantial claim - Interpretationreasoning
Developing vectors to treat many retinal diseases, such as Usher's Syndrome Type 2A, is virtually impossible due to AAV size limitation.
“As a result, developing vectors to treat many retinal diseases, such as Usher's Syndrome Type 2A, which is caused by a mutation in a gene with a 15.8 kb coding region, is virtually impossible.”
Quote in the paperSubstantial claim - Interpretationreasoning
There may be an inherent limit for vector reconstitution after dual AAV delivery.
“Therefore, these studies may suggest an inherent limit for vector reconstitution after dual AAV delivery.”
Quote in the paperSubstantial claim - Premisecitation
mRNA length has been shown to negatively correlate with stability.
“In particular, mRNA length has been shown to negatively correlate with stability, which would explain our observations (Feng and Niu, 2007).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Feng and Niu, 2007 source
- Interpretationown data
HB was distinctly the most efficient dual vector strategy in vivo.
“Further in vivo experiments were only performed with HB vectors, as it proved to be distinctly the most efficient strategy.”
Quote in the paperSubstantial claim - Interpretationreasoning
The OL strategy would result in different reconstitution efficiencies for every transgene.
“As such, the OL strategy would result in different reconstitution efficiencies for every transgene.”
Quote in the paperSubstantial claim - Interpretationown data
When targeting retinal cells that are efficiently transduced by AAV, protein expression levels of ~10% of monocistronic vector levels may be achieved.
“When targeting retinal cells that are efficiently transduced by AAV, protein expression levels of ~10% of monocistronic vector levels may be achieved.”
Quote in the paperSubstantial claim - Interpretationown data
Protein expression levels may not be a reliable indicator of actual reconstitution efficiency.
“However, this may not be a reliable indicator of actual reconstitution efficiency.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 23
- May combine two claims. 23
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationThe three dual approaches have been used to express MYO7A and ABCA4 genes and showed effective in vitro protein expression.
“Furthermore, the three dual approaches (trans-splicing, overlapping or “hybrid” techniques) have been used to express the MYO7A and the ABCA4 genes (both with CDS over 6 kb in length and expressed in the retina) and showed effective in vitro protein expression (Dyka et al., 2014).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Dyka et al., 2014 source
The Results section (page not provided) reports full-length MYO7A protein expression in HEK293 cells using the dual-vector approaches. The Discussion mentions in vitro ABCA4 expression, but says the simple-overlap approach was highly inefficient relative to other platforms; it does not establish effective expression of ABCA4 with all three approaches. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationThe difference between OL reconstitution in RPE cells and photoreceptors may be due to differences in overlap lengths and sequences.
“Even though others have detected OL reconstitution in RPE cells, but not photoreceptors, this may be due to differences in overlap lengths and sequences (Trapani et al., 2015).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Trapani et al., 2015 source
The Results section on recombinogenic regions (page unavailable) compares different homology sequences and reports differences in how frequently they yield ABCA4 expression in mouse photoreceptors. It also notes lower recombination-based vector efficiency in photoreceptors than in cell culture. It does not compare overlapping-vector reconstitution in RPE cells and photoreceptors or attribute such a difference to overlap length and sequence. (LLM, conf=0.77)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationBoth transcription and translation are strongly affected by exact DNA and mRNA sequences, respectively, as well as their cellular environments.
“Both transcription and translation are strongly affected by exact DNA and mRNA sequences, respectively, as well as their cellular environments (Sonenberg and Hinnebusch, 2009; Alpert et al., 2017).”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Sonenberg and Hinnebusch, 2009 source
The Introduction (page not available in our copy) explains that mRNA sequences and structures affect translation initiation, while cellular conditions such as starvation or stress can alter translation. It does not establish the corresponding claim that DNA sequence and cellular environment affect transcription. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites Alpert et al., 2017 source
The Abstract states that DNA sequence, gene architecture, and chromatin regulate transcription elongation rates; the Introduction also discusses cell signaling and environmental cues as possible constraints. The paper does not address whether mRNA sequence or cellular environment strongly affects translation, so it supports the transcription part but not the full sentence attributed to it. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOthers have detected OL reconstitution in RPE cells, but not photoreceptors.
“Even though others have detected OL reconstitution in RPE cells, but not photoreceptors, this may be due to differences in overlap lengths and sequences (Trapani et al., 2015).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Trapani et al., 2015 source
The Results section reports photoreceptor expression from dual AAV hybrid vectors, while its RPE measurements concern lipofuscin. I searched for overlapping-vector (OL) reconstitution in RPE cells but not photoreceptors; the retrieved passages do not report that comparison. No page number was supplied for these passages. (LLM, conf=0.70)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationAAV8 and Anc80L65 both transduce retinal cells with high efficiencies.
“Effect of serotype on vector reconstitution was studied by comparing AAV8 and Anc80L65, both of which transduce retinal cells with high efficiencies (Zinn et al., 2015).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Zinn et al., 2015 source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationVector reconstitution has been reported in vitro in several cell lines, and in vivo in mouse liver, skeletal muscle, and retina.
“Vector reconstitution has been reported in vitro in several cell lines, and in vivo in mouse liver, skeletal muscle, and retina (Grieger and Samulski, 2005).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Grieger and Samulski, 2005 source
The introductory passage labelled Abstract describes split-vector systems that rely on recombination of two vector genomes within a cell, supporting the general idea of vector reconstitution. It does not report reconstitution in several cell lines or in mouse liver, skeletal muscle, or retina. The Results describe transduction of cultured cells, not those specific reconstitution findings; page numbers are unavailable in our copy. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationDifferent relative efficiencies of dual AAV vectors have been reported by others, especially regarding HB and TS.
“Interestingly, different relative efficiencies have been reported by others, especially regarding HB and TS (Dyka et al., 2014; Trapani et al., 2014).”
Quote in the paperNot a substantial claim2 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationVector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A.
“Even though vector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
Quote in the paperSubstantial claim3 of 3 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAn alternate method for expressing large proteins relying on intein protein sequences has been reported.
“An alternate method for expressing large proteins relying on intein protein sequences has also been reported (Li et al., 2008; Truong et al., 2015; Chew et al., 2016).”
Quote in the paperNot a substantial claim2 of 3 sources checkedMay combine two claims.
Findingown dataIn vitro, dual vector dose increases of 10-fold and 100-fold resulted in 17-fold and 102-fold increases in reporter transgene expression, respectively.
“We also studied whether the effect of dose of dual vector transduction correlates linearly with reporter transgene expression in vitro, and detected 17 and 102-fold increases in expression when dual vector dose was increased 10 and 100-fold to controls, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn vitro, reconstitution efficiencies based on protein expression normalized to controls were 15.3% for HB, 17.4% for OL, and 10.3% for TS.
“When reconstitution efficiencies based on protein expression were quantified by normalizing lacZ expression levels to their respective controls, levels of 15.3, 17.4, and 10.3% were detected for HB, OL and TS, respectively.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataFunctionality of dual vectors and controls was assessed in vitro, and protein expression from oversized reporter was similar to normal sized controls.
“Functionality of our dual vectors and controls was assessed in vitro, and showed that protein expression from oversized reporter was similar to normal sized controls.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn vivo in mouse retina, dual vector reconstitution efficiencies were 9.07% of control for HB and 1.78% for TS.
“Reconstitution efficiencies were 9.07 and 1.78% of control for HB and TS, respectively (Figure 3A).”
- Also stated in: § Discussion · hedged
“Our data indicates different relative efficiencies of reconstitution in vivo in mouse retina with levels compared to control, of 9.07% for HB, 1.78% for TS, and below detection for OL.”
Quote in the paperSubstantial claim- Also stated in: § Discussion · hedged
May combine two claims.
Findingown dataIn vivo, reconstitution efficiency was assessed to be ~10% based on protein activity, while mRNA amounts suggested ~60% efficiency.
“While reconstitution efficiency was assessed to be ~10% based on protein activity, mRNA amounts suggested ~60% efficiency.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S4 (based).
Interpretationnone givenEach dual AAV approach will result in reconstitution of transcriptionally active Rainbow construct.
“Each approach will result in reconstitution of transcriptionally active Rainbow construct.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe rate of rAAV genome reconstitution may be quantifiable, but resulting mRNA or protein levels are not, unless controls of identical sequences are used.
“Rate of rAAV genome reconstitution may be quantifiable, but resulting mRNA or protein levels are not, unless controls of identical sequences are used.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenTransfection experiments were done in triplicates with identical conditions to ensure equal transfection efficiencies.
“Transfection experiments were done in triplicates with identical conditions to ensure equal transfection efficiencies.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based).
Study design and conductnone givenThe lacZ primer/probe assay was specifically designed to span the exact location where the lacZ gene is split into left and right constructs in the dual hybrid strategy.
“The lacZ primer/probe assay was specifically designed to span the exact location where the lacZ gene is split into left and right constructs in the dual hybrid strategy.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Interpretationnone givenThe drastic decrease in OL efficiency in vivo may reflect differences in activities of pathways responsible for homologous recombination in vivo as compared to in vitro.
“The drastic decrease in OL efficiency may reflect differences in activities of pathways responsible of homologous recombination in vivo as compared to in vitro.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationPackaged AAV genomes never exceeded 5.2 kb in length, but overpackaging results in genome fragmentation.
“A study by Wu et al. (2010) showed that packaged AAV genomes never exceeded 5.2 kb in length, but overpackaging results in genome fragmentation.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Wu et al., 2010
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Interpretationown dataThe TS approach has several different ways that the left and right vectors could come together, which overall lowers the probability of correct concatamerization and consequently reconstitution efficiency.
“As we show in Figure 1E, there are several different ways that the left and right vectors from the TS approach could come together, which overall lowers the probability of correct concatamerization and consequently reconstitution efficiency.”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductreasoningCorrect reconstitution can be accurately quantified by measuring β-galactosidase with standard enzymatic assays because neither left nor right constructs contains a full lacZ coding sequence.
“As neither left nor right constructs contains a full lacZ coding sequence, correct reconstitution can be accurately quantified by measuring the amount of its protein product, β-galactosidase, with standard enzymatic assays.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationDual AAV approaches can partially overcome the size limitation and deliver larger transgenes.
“Previous studies have demonstrated that homologous recombination and/or inverted terminal repeat (ITR) mediated concatemerization of two overlapping AAV vectors can partially overcome the size limitation and help deliver larger transgenes.”
- Also stated in: § Introduction · plain
“It has been shown that the fragments will reassemble when transferred to a cell and produce a full-length protein (Yan et al., 2000, 2002; Duan et al., 2003; Hirsch et al., 2009).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Yan et al., 2000, 2002; Duan et al., 2003; Hirsch et al., 2009
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Also stated in: § Introduction · plain
Probably not a substantial claim: may not pass S4 (based).
InterpretationreasoningReconstitution based on uniform homologous sequences, such as in the hybrid approach, should result in equal efficiencies regardless of the transgene.
“In contrast, reconstitution based on uniform homologous sequences, such as in the hybrid approach, should result in equal efficiencies regardless of the transgene.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn the retina, the dual approach was first reported by Reich et al. (2003) using trans-splicing to show β-galactosidase expression in vivo around 40% after AAV5 subretinal injection.
“In the retina, the dual approach was first reported by Reich et al. (2003) which used the trans-splice technique to show that β-galactosidase expression in vivo was around 40% after AAV5 subretinal injection (Reich et al., 2003).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Reich et al., 2003 source
Classified as probably not a substantial claim. May combine two claims.
Interpretationnone givenOriginal Rainbow sequence is anticipated to be restored only after OL reconstitution, whereas TS will have an intron containing an AAV ITR sequence, and HB will have an intron with AP or AP-ITR-AP sequence.
“Original Rainbow sequence is anticipated to be restored only after OL reconstitution, whereas TS will have an intron containing an AAV ITR sequence, and HB will have an intron with AP or AP-ITR-AP sequence (Figures 1D,E).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAll animal procedures were performed in accordance with protocols approved by institutional animal care and use committees at SERI and conformed to ARVO guidelines.
“All animal procedures were performed in accordance with protocols approved by the institutional animal care and use committees at SERI and conformed to the guidelines on the care and use of animals adopted by the Association for Research in Vision and Ophthalmology (Rockville, MD).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationThe drastic differences in HB reconstitution within AP intron sequence seen between different studies may reflect undetected or unreported mutations between sequences, especially in the ITRs, indicating sensitivity of reconstitution to minor variations.
“While all designs seemingly use sequences originally reported by Ghosh et al. (2008), the drastic differences in HB reconstitution within AP intron sequence seen between the different studies, may reflect undetected or unreported mutations between sequences, especially in the ITRs, indicating sensitivity of reconstitution to minor variations (Ghosh et al., 2008).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Ghosh et al., 2008 source
May combine two claims.
InterpretationreasoningRegulatory sequences required to drive gene expression add to the final size and may render many genes too large for AAV packaging.
“Moreover, regulatory sequences that may be required to drive gene expression add to the final size and may render many genes too large for AAV packaging.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable), S4 (based).
Interpretationnone givenFor clinical purposes, dual AAV approaches may be feasible if sufficient protein expression levels to affect the disease phenotype can be achieved, regardless of the de facto efficiency of the reconstitution process.
“For clinical purposes, dual AAV approaches may be feasible if sufficient protein expression levels to affect the disease phenotype can be achieved, regardless of the de facto efficiency of the reconstitution process.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Interpretationnone givenOL reconstitution depends on the recombinogenic capacity of the sequence, which is expected to be gene-dependent.
“and on the recombinogenic capacity of this sequence, which is expected to be gene-dependent.”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductreasoningAn enzymatic assay identifies reconstitution based on protein function, not just size, thus excluding potential incorrect reconstitution events.
“Further, an enzymatic assay identifies reconstitution based on protein function, not just size, thus excluding potential incorrect reconstitution events.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationIn the intein approach, the transgene is divided into two parts, with the 5′ half expressing a C-terminal intein sequence and the 3′ half an N-terminal intein sequence.
“In this approach, the transgene is divided into two parts in which 5′ half of the gene will express a C-terminal intein sequence, and 3′ half an N-terminal intein sequence.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningAs of now, dual AAV vector strategies may be of use in gene therapy modalities where even limited transgene expression has positive effects on disease phenotype.
“As of now, dual AAV vector strategies may be of use in gene therapy modalities where even limited transgene expression has positive effects on disease phenotype.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
InterpretationreasoningInteins are of bacterial origin and may be immunogenic.
“Finally, inteins are of bacterial origin, and as such may be immunogenic.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningIn the intein approach, both vector halves need separate transcriptional regulators, and the added length of intein sequences diminishes gain of payload carrying capacity compared to genome reconstitution approaches.
“Also, as the two peptides need to be expressed, both vector halves will need their separate transcriptional regulators, and with the added length of the intein sequences, gain of payload carrying capacity is diminished as compared to genome reconstitution approaches.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisereasoningReconstitution in the intein approach takes place on peptide level in a process termed protein splicing, where the intein sequences excise themselves and join the remaining peptides together.
“Reconstitution will therefore take place on peptide level in a process termed protein splicing, where the intein sequences excise themselves and join the remaining peptides together.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Interpretationnone givenProteins can be split by inteins only at certain sites, and the reconstituted protein may not reach proper conformation due to the two peptides folding separately.
“Further, proteins can be split by inteins only at certain sites, and the reconstituted protein may not reach proper conformation due to the two peptides folding separately.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationCo-transduction can also be achieved by intravitreal injection, which targets the retinal ganglion cells and inner retina, albeit at much lower efficiencies than by subretinal injections.
“However, co-transduction can also be achieved by intravitreal injection, which targets the retinal ganglion cells and inner retina (Hung et al., 2016), albeit at much lower efficiencies than by subretinal injections.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Hung et al., 2016 source
The paper relies on this without support.
A more fundamental understanding of vector reconstitution efficiencies has been lacking.
“Even though the dual AAV method feasibility has been demonstrated by rescue of disease phenotype in different models, a more fundamental understanding of vector reconstitution efficiencies has been lacking.”
The paper relies on this without support.
The low efficiency of AAV dual strategies remains a hurdle for further ocular translational applications, even when using vectors with extremely high retinal transduction capacity like AAV8.
“Furthermore, despite promising results, the low efficiency of AAV dual strategies remains a hurdle for further ocular translational applications, even when using vectors with extremely high retinal transduction capacity like AAV8.”
The paper relies on this without support.
The dual AAV method feasibility has been demonstrated by rescue of disease phenotype in different models.
“Even though the dual AAV method feasibility has been demonstrated by rescue of disease phenotype in different models, a more fundamental understanding of vector reconstitution efficiencies has been lacking.”
The paper relies on this without support.
Several important candidate genes for gene replacement therapies, such as USH2A, F8 or DMD, are too large for AAV.
“several important candidate genes for gene replacement therapies, such as USH2A (Usher syndrome type 2A), F8 (hemophilia A) or DMD (Duchenne muscular dystrophy), are too large.”
The paper relies on this without support.
Dual AAV vector strategies rely on rAAV genome concatamerization utilizing ITRs and/or transgene cassette sequence homologies.
“Dual AAV vector strategies rely on rAAV genome concatamerization utilizing ITRs and/or transgene cassette sequence homologies.”
The paper relies on this without support.
In vivo efficiencies of dual AAV vectors of ~5–10% compared to single AAV approaches have been reported.
“Depending on experimental details, in vivo efficiencies of ~5–10% as compared to transgene expression from single AAV approaches have been reported”
The paper relies on this without support.
In some model systems, dual AAV vector reconstitution has resulted in rescue of a disease phenotype.
“and in some model systems this has resulted in rescue of a disease phenotype”
The paper relies on this without support.
Studies comprehensively comparing efficiencies of different dual AAV vector strategies in the retina have been limited.
“Studies comprehensively comparing efficiencies of different dual AAV vector strategies in the retina have been limited.”
The paper relies on this without support.
Proof of concept studies have shown feasibility of the intein approach, but its efficiency has never been thoroughly characterized.
“Even though proof of concept studies have shown feasibility of this approach, its efficiency has never been thoroughly characterized.”
The paper relies on this without support.
Details behind cellular mechanisms underlying vector reconstitution are still poorly understood.
“However, even though dual AAV vector strategies have been shown to work, details behind cellular mechanisms underlying vector reconstitution are still poorly understood.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The hybrid dual AAV strategy was initially proposed by Gosh and colleagues in 2008 and found to significantly improve transgene reassembly in a variety of studies thereafter.
“The hybrid dual AAV strategy was initially proposed by Gosh and colleagues in 2008 [54] and found to significantly improve transgene reassembly in a variety of studies thereafter [29,49].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [49]
The Abstract and Discussion report that the hybrid approach gave the best reconstitution in vivo in mouse retina, and the Introduction says multiple studies found hybrid and trans-splicing among the most efficient dual-AAV approaches. But the Results report higher in-vitro reconstitution for the overlap approach than for hybrid, so this paper does not establish a consistent, significant improvement across a variety of studies. The separate attribution of the strategy’s 2008 origin is attached to a different citation. (LLM, conf=0.84)
Experimental — accuracy not yet measuredOverlapping vectors were not as successful in terminally differentiated photoreceptors, suggesting some targets may be intrinsically more refractory to this approach.
“Contrarily, overlapping vectors were not as successful in terminally differentiated photoreceptors [29,49], suggesting that some targets may be intrinsically more refractory to this approach.”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Hybrid is called best in vitro despite higher overlap efficiency
MajorThe abstract says the hybrid approach performed best in vitro, but the reported in vitro reconstitution efficiency was 17.4% for overlap versus 15.3% for hybrid.
“the hybrid approach relying on vector genome concatemerization by highly recombinogenic sequences and ITRs sequence overlap offers the best levels of reconstitution both in vitro and in vivo compared to trans-splicing and overlap strategies.”
“Based on β-galactosidase levels, reconstitution efficiencies were 10.3, 15.3, and 17.4% of control for TS, HB, and OL, respectively (Figure 2B).”
High-dose group received tenfold, not fivefold, the total viral genomes
MinorThe high-dose group received 1.5E10 vg/eye of each of two constructs, or 3E10 vg/eye total. That is ten times the low-dose group's stated total of 3E9 vg/eye, not five times.
“which generated a final titer of 7.5E12 vg/ml (1.5E10 vg/eye) of each construct. As a result, the “high dose” group received 5 times more vg than the “low dose” group.”
“For the combination of left (L) and right (R) constructs (low dose group), viral genomes (vg) were diluted together to generate a final titer of 1.5E12 vg/ml (total 3E9 vg/eye).”
Cites
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304 · see citing works
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184 · cited 2× · see citing works
“, 2016), and promising results from numerous ongoing clinical trials may herald the emergence of other products in the near future (Naldini, 2015; Pierce and Bennett, 2015).”
BackgroundEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,025 · see citing works
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · see citing works
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · see citing works
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617 · see citing works
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461 · see citing works
Self-citationGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419 · see citing works
Development of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371 · see citing works
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310 · see citing works
Self-citationTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · see citing works
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269 · see citing works
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · see citing works
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161 · see citing works
The Status ofRPE65Gene Therapy Trials: Safety and EfficacyPreprint
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 151 · see citing works
Self-citationExpressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids
Chamberlain, K., Riyad, J. M., & Weber, T. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.140 · Cited by 141 · cited 1× · see citing works
“Consequently, there is great interest in increasing transgene size while still utilizing the AAV system and the use of a dual AAV vectors system has been extensively studied for different experimental and disease modalities (Chamberlain et al., 2016).”
BackgroundDyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128 · see citing works
AAV-mediated CRISPR/cas gene editing of retinal cells in vivo
Hung, S. S. C., Chrysostomou, V., Li, F., Lim, J. K. H., Wang, J.-H., Powell, J. E., Tu, L., Daniszewski, M., Lo, C., Wong, R. C., et al. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19316 · Cited by 125 · see citing works
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120 · see citing works
Protein Trans -Splicing as a Means for Viral Vector-Mediated In Vivo Gene Therapy
Li, J., Sun, W., Wang, B., Xiao, X., & Liu, X. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.009 · Cited by 115 · see citing works
Yan, Z., Zak, R., Zhang, Y., & Engelhardt, J. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.364-379.2005 · Cited by 107 · see citing works
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103 · see citing works
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100 · see citing works
Perfect timing: splicing and transcription rates in living cells
Alpert, T., Herzel, L., & Neugebauer, K. M. (2017) · WIREs RNA · doi:10.1002/wrna.1401 · Cited by 99 · see citing works
Reich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., & Bennett, J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464697 · Cited by 96 · see citing works
Self-citationTrapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94 · see citing works
Boye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79 · see citing works
Relationship between mRNA stability and length: an old question with a new twist
Feng, L., & Niu, D.-K. (2007) · Biochemical Genetics · doi:10.1007/s10528-006-9059-5 · Cited by 58 · see citing works
Recombinant AAV-mediated gene delivery using dual vector heterodimerization.
Yan, Z.-Y., Ritchie, T., Duan, D., & Engelhardt, J. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)46065-x · Cited by 26 · see citing works
AAV Recombineering with Single Strand Oligonucleotides
Hirsch, M. L., Storici, F., Li, C., Choi, V. W., & Samulski, R. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007705 · Cited by 26 · see citing works
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2003) · Viral Vectors for Gene Therapy · doi:10.1385/1-59259-304-6:287 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Levy, J. M., Yeh, W.-H., Pendse, N. D., Davis, J. R., Hennessey, E., Butcher, R. M., Koblan, L. W., Comander, J., Liu, Q., & Liu, D. R. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0501-5 · Cited by 472 · see citing works
Al‐Moyed, H., Cepeda, A. P., Jung, S., Moser, T., Kügler, S., & Reisinger, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809396 · Cited by 230 · see citing works
“Nevertheless, improving the large transgene reconstitution efficacy by simply increasing the amount of available vector genomes does not improve protein expression levels as shown for dual-AAV vectors in the retina (Carvalho et al, 2017).”
BackgroundMcClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92 · see citing works
“0 kb overlap regions of a lacZ gene in an overlapping dual vector system and identified the largest overlap region as being the most efficient.(11) However, in another report, a 0.”
BackgroundSuprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84 · see citing works
mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
Riedmayr, L. M., Hinrichsmeyer, K. S., Thalhammer, S. B., Mittas, D. M., Karguth, N., Otify, D. Y., Böhm, S., Weber, V. J., Bartoschek, M. D., Splith, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42386-0 · Cited by 87 · see citing works
Fu, X., Chen, W.-C., Argento, C., Clarner, P., Bhatt, V., Dickerson, R., Bou-Assaf, G., Bakhshayeshi, M., Lu, X., Bergelson, S., et al. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.088 · Cited by 77 · see citing works
“24,25 The net charge of each of these AAV subpopulations is often very similar to that of empty or full capsids, resulting in coelution of these species with the empty or full capsids during an elution gradient.”
Retinitis Pigmentosa: Novel Therapeutic Targets and Drug Development
Wu, K. Y., Kulbay, M., Toameh, D., Xu, A. Q., Kalevar, A., & Tran, S. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020685 · Cited by 81 · see citing works
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76 · see citing works
Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73 · see citing works
“A number of studies have indeed shown the ability of these strategies to reconstitute large transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of animal models of IRDs…”
BackgroundResultInfluentialCell and gene therapy for kidney disease
Peek, J. L., & Wilson, M. H. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00702-3 · Cited by 77 · see citing works
Optic nerve regeneration screen identifies multiple genes restricting adult neural repair
Lindborg, J. A., Tran, N. M., Chenette, D. M., DeLuca, K., Foli, Y., Kannan, R., Sekine, Y., Wang, X., Wollan, M., Kim, I.-J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108777 · Cited by 70 · see citing works
“Because dual AAV injections may reduce infection efficiency in vivo (Carvalho et al., 2017), we used Cas9 transgenic mice in conjunction with single AAV delivery of sgRNAs at 10(12)–10(13) genome copies/mL.”
MethodAdeno-Associated Virus Genome Interactions Important for Vector Production and Transduction
Maurer, A. C., & Weitzman, M. D. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.069 · Cited by 65 · see citing works
Design of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 64 · see citing works
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 61 · see citing works
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T., Barathi, V. A., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 58 · see citing works
“Alternatively, a splicing acceptor and splice donor can be added to the termini to enable intermolecular concatamerization and splicing of the two halves into a single contiguous cDNA construct (Carvalho et al., 2017).”
BackgroundMarrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56 · see citing works
“and found to significantly improve transgene reassembly in a variety of studies thereafter [29,49].”
BackgroundDyka, F. M., Molday, L. L., Chiodo, V. A., Molday, R. S., & Hauswirth, W. W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.132 · Cited by 56 · see citing works
Development of New Strategies Using Extracellular Vesicles Loaded with Exogenous Nucleic Acid
Orefice, N. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080705 · Cited by 56 · see citing works
“, by oversized AAV vector genomes) [63,64] and achieve a higher transduction efficiency and specificity for relevant target tissues.”
BackgroundHas retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 51 · see citing works
“Yet, the studies performed so far have shown that none of the dual AAV approaches match the levels of expression achieved with a single AAV vector (63,68,69) and this might be limiting for specific applications.”
BackgroundRNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51 · see citing works
Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear
Akil, O. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107912 · Cited by 47 · see citing works
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40 · see citing works
“Even if the reconstitution efficiency is low, phenotypic improvement in disease models have been reported in previous studies.(52,54,55) Furthermore, some genes involved in genetic disease are still larger than dual-AAVs capacity.”
ResultHair Cell Transduction Efficiency of Single- and Dual-AAV Serotypes in Adult Murine Cochleae
Omichi, R., Yoshimura, H., Shibata, S. B., Vandenberghe, L. H., & Smith, R. J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.007 · Cited by 42 · see citing works
“Importantly, while co-transduction is a minimum requirement, several other processes need to occur for OTOF protein expression to be realized, including concatemer formation to permit correct trans-splicing.(31) Our results establish the extent to which co-transduction may be rate limiting and demonstrate that for IHC…”
BackgroundSelf-citationFocused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41 · see citing works
Self-citationDual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37 · see citing works
Retinal cadherins and the retinal cadherinopathies: Current concepts and future directions
Yusuf, I. H., Garrett, A. M., MacLaren, R. E., & Issa, P. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101038 · Cited by 35 · see citing works
Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome
Grimm, N.-B., & Lee, J. T. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.007 · Cited by 33 · see citing works
A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome
French, L. S., Mellough, C., Chen, F. K., & Carvalho, L. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00183 · Cited by 33 · see citing works
Self-citationResearch Models and Gene Augmentation Therapy for CRB1 Retinal Dystrophies
Boon, N., Wijnholds, J., & Pellissier, L. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00860 · Cited by 31 · see citing works
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 33 · see citing works
dCas9-VPR-mediated transcriptional activation of functionally equivalent genes for gene therapy
Riedmayr, L. M., Hinrichsmeyer, K. S., Karguth, N., Böhm, S., Splith, V., Michalakis, S., & Bećirović, E. (2022) · Nature Protocols · doi:10.1038/s41596-021-00666-3 · Cited by 31 · see citing works
Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA
Dooley, S. J., McDougald, D. S., Fisher, K. J., Bennicelli, J. L., Mitchell, L. G., & Bennett, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.014 · Cited by 28 · see citing works
“Lastly, efforts have been made to break the coding DNA sequence of a large gene into fragments across multiple viral genomes.(11,12) When applied to LCA10, two AAV genomes are designed with either the 50 or 30 half of CEP290 along with elements required to reconstitute the open”
MethodSelf-citationFakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 29 · see citing works
CRISPR/Cas based gene editing: marking a new era in medical science
Prasad, K. M., George, A., Ravi, N. S., & Mohankumar, K. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06479-7 · Cited by 27 · see citing works
“For in-vivo genome editing a new strategy like AAV based cas9 delivery system was developed [33, 34], which acts as a stand-alone system without being coalesced with an additional delivery system.”
MethodFuture Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases
Hansen, S., McClements, M. E., Corydon, T. J., & MacLaren, R. E. (2023) · Cells · doi:10.3390/cells12030440 · Cited by 25 · see citing works
Kansara, V. S., Cooper, M. J., Sesenoglu‐Laird, O., Muya, L. W., Moen, R. C., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.21 · Cited by 24 · see citing works
Paul, A., Collins, M. G., & Lee, H. Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.899209 · Cited by 23 · see citing works
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21 · see citing works
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 24 · see citing works
Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20 · see citing works
Corydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 19 · see citing works
Pathogenesis and Treatment of Usher Syndrome Type IIA
Zaw, K., Carvalho, L. S., Aung-Htut, M. T., Fletcher, S., Wilton, S. D., Chen, F. K., & McLenachan, S. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000546 · Cited by 21 · see citing works
Self-citationBase and Prime Editing in the Retina—From Preclinical Research toward Human Clinical Trials
Yee, T., & Wert, K. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012375 · Cited by 18 · see citing works
“Unfortunately, editing efficiency generally decreases with dual-AAV, due to the need for simultaneous transduction of multiple AAVs [37].”
BackgroundHuang, J., Li, J., Xu, X., & Li, K. (2025) · Biomolecules · doi:10.3390/biom15070940 · Cited by 18 · see citing works
“Despite these advances, DNA-level reconstitution raises several concerns [107].”
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B., & Lee, J. (2024) · eLife · doi:10.7554/elife.89782.2 · Cited by 18 · see citing works
Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system
Datta, P., Rhee, K.-D., Staudt, R. J., Thompson, J. M., Hsu, Y., Hassan, S., Drack, A. V., & Seo, S. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae144 · Cited by 17 · see citing works
McClements, M. E., Barnard, A. R., Charbel Issa, P., & MacLaren, R. E. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.20 · Cited by 18 · see citing works
Ferreira, M. V., Fernandes, S., Almeida, A. I., Neto, S., Mendes, J. P., Silva, R. J. S., Peixoto, C., & Coroadinha, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310524 · Cited by 16 · see citing works
“/eye of each vector in vivo pre-clinical studies [4,19].”
BackgroundRiaz, S., Sethna, S., Duncan, T. E., Naeem, M. A., Redmond, T. M., Riazuddin, S. A., Riazuddin, S., Carvalho, L. S., & Ahmed, Z. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.017 · Cited by 15 · see citing works
Self-citationDual AAV vectors for efficient delivery of large transgenes
Mittas, D. M., Riedmayr, L. M., Gavrilov, Z., Weber, V. J., Otify, D. Y., Mehlfeld, V., Szalontai, B., Ucambarlic, E., Gandor, C. L. A., Heigl, T., et al. (2025) · Nature Protocols · doi:10.1038/s41596-025-01243-8 · Cited by 16 · see citing works
Pasquini, G., Cora, V., Swiersy, A., Achberger, K., Antkowiak, L., Müller, B., Wimmer, T., Fraschka, S. A. K., Casadei, N., Ueffing, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041380 · Cited by 14 · see citing works
“Yet, many IRDs, such as Stargardt disease associated with mutations in the ABCA4 gene, cannot be treated with gene supplementation therapy: The underlying genes do not meet the cargo size requirements of state-of-the-art and approved viral vector systems (Figure 1a); and dual adeno-associated virus (AAV) vector system…”
BackgroundWu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 12 · see citing works
Shamsnajafabadi, H., Kaukonen, M. K., Bellingrath, J.-S., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Genes · doi:10.3390/genes15050625 · Cited by 11 · see citing works
“Various strategies have been developed to address AAVs’ limited package capacity, such as utilizing a minimal CMV promoter [61], dual-or triple-AAV approaches [62,63], and increasing packaging capacity [62].”
MethodRNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies
Garanto, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_12 · Cited by 11 · see citing works
Recovery kinetics of dual AAV-mediated human otoferlin expression
Sellon, J. B., So, K. S., D'Arcangelo, A., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1376128 · Cited by 10 · see citing works
“Therefore, the use of hybrid dual vectors as a gene therapy approach for delivering large genes in vivo provides a promising approach (Carvalho et al., 2017; Akil et al., 2019; Al-Moyed et al., 2019), while the timing, efficiency of transduction, generation of full-length mRNA, and protein…”
BackgroundMaurer, A. C., Benyamini, B., Whitney, O. N., Fan, V. B., Cattoglio, C., Kissiov, D. U., Dailey, G. M., Darzacq, X., Weitzman, M. D., & Tjian, R. (2025) · Nature Communications · doi:10.1038/s41467-025-56738-5 · Cited by 9 · see citing works
Co-transduction of dual-adeno-associated virus vectors in the neonatal and adult mouse utricles
Chen, Z.-R., Guo, J., He, L., Liu, S., Xu, J.-Y., Yang, Z.-J., Su, W., Liu, K., Gong, S., & Wang, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1020803 · Cited by 10 · see citing works
Schultz, A., Cheng, S.-Y., Kirchner, E. G., Costello, S. M., Miettinen, H. M., Chaverra, M. E., King, C., George, L., Zhao, X., Narasimhan, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45376-w · Cited by 9 · see citing works
“Alternatively, concatamerization of dual AAV vectors 30–34 can be considered as the ELP1 transgene is large (4 kb), making packaging challenging.”
BackgroundChoi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B., & Lee, J. (2023) · eLife · doi:10.7554/elife.89782 · Cited by 29 · see citing works
“We speculate that (1) insufficient dosage due to difficulty in producing high titer viral package for big cargo (i.e. 5 KB) ( Levy et al., 2020 ; Wu et al., 2010 ), (2) limited delivery ( Carvalho et al., 2017 ), and/or (3) difficulty in targeting the very long CAG repeat resulted in modest effects.”
BackgroundBellingrath, J.-S., McClements, M. E., Kaukonen, M. K., Fischer, M. D., & MacLaren, R. E. (2021) · Genes · doi:10.3390/genes12121908 · Cited by 9 · see citing works
“7kb packaging capacity of an AAV vector [44,45].”
BackgroundAdvances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9 · see citing works
Current approaches for Usher syndrome disease models and developing therapies
Leith, F. K., Lye, J., Delaney, D. S., McLenachan, S., Chen, F. K., Atlas, M. D., & Wong, E. Y. M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1547523 · Cited by 7 · see citing works
Peek, J. L., Rosales, A., Qi, J., Feleke, L., Menshikh, A., Welch, R. C., Woodard, L. E., Asokan, A., & Wilson, M. H. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201736 · Cited by 6 · see citing works
Fehrman, R. L., Chern, K. J., Stoltz, K. P., & Lipinski, D. M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110223 · Cited by 5 · see citing works
Advances in base editing with an emphasis on an AAV-based strategy
Kuang, J., Lyu, Q., Wang, J., Cui, Y., & Zhao, J. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.015 · Cited by 5 · see citing works
Retinitis Pigmentosa and Therapeutic Candidates
Livingston, C. A., Weng, C. Y., & Chancellor, J. R. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000542 · Cited by 4 · see citing works
“22 Furthermore, novel AAV capsids allow for intravitreal delivery, alleviating the invasiveness of administration.”
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B. P., & Lee, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.28.538700 · Cited by 4 · see citing works
Toward improved AAV gene therapies for retinal disorders: challenges and advances
Siontas, O., Brown, M., & Ahn, S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2544497 · Cited by 3 · see citing works
Wada, H., Hama, N., Hasegawa, K., Takamuku, C., Yoshida, M., Omura, M., Araki, A., & Kuwako, K.-I. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.055 · Cited by 3 · see citing works
Al‐Moyed, H. (2019) · doi:10.53846/goediss-7430 · Cited by 3 · see citing works
Fehrman, R. L., & Lipinski, D. M. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.11.38 · Cited by 2 · see citing works
Haar, J., Krämer, C., & Grimm, D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0755-8_5 · Cited by 2 · see citing works
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B. P., & Lee, J. (2023) · eLife · doi:10.7554/elife.89782.1 · Cited by 2 · see citing works
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1 · see citing works
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1 · see citing works
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1 · see citing works
Vasconcelos, H., Sallum, J. M. F., & Maia, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_19-1
One down but many more to go: the state of gene therapy for inherited retinal disease
Tan, T., Sun, C., Poh, S. S. J., Lim, J., Teo, J. X. J., Dey, S., Chua, Z., Guo, J., Wang, Z., Tay, H. G., et al. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2571360
Synaptopathies auditives et vestibulaires : de la physiologie moléculaire à la thérapie génique
Calvet, C. (2020) · theses.fr (ABES) · doi:10.70675/8920e327zd8ffz457ez9711zcfc53af428dc
Advances and clinical potential of epigenome editing
Choi, I., Kim, S., & Baek, I. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06311-0
“Increasing vector doses to improve co-transduction is challenging because high AAV titers can trigger unwanted immune responses against both the viral vector and the expressed dCas proteins [157, 158 ].”
Spatiotemporal precision in gene editing: Stimulus-responsive delivery of CRISPR-Cas RNPs
Murthy, M. K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108832
Vasconcelos, H., Sallum, J. M. F., & de Carvalho, A. C. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_19
Gene Therapy for Corneal Diseases
Bhujel, B., Eah, K. S., Kang, S. S., Chung, H. S., & Kim, J. Y. (2026) · BioTech · doi:10.3390/biotech15040080 · Cited by 1 · see citing works
- Authors
- Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- University of Pennsylvania (US)
- Corresponding author
- Vandenberghe, Luk H.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-09-08
- Volume
- 11
- Pages
- 503-503
- ISSN
- 1662-453X (ISSN-L)
- PMC
- PMC5596095
- OpenAlex
- W2746153430
- Cited by
- 86
- References
- 31
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 7 · 2023: 14 · 2022: 11 · 2021: 10 · 2020: 17 · 2019: 8 · 2018: 3
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Grousbeck Family Foundation
- Foundation Fighting Blindness (TA-GT -0611 -0571 -SCHMEE-WG)
- National Institutes of Health (5DP1EY023177)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- retinal gene therapy, recombinant adeno-associated virus, inverted terminal repeats, homologous recombination, trans-splicing, RPE65, inherited retinal degeneration, mouse retina
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review